Gujarat kidney and super speciality Limited successfully concluded its postal ballot process on 25-04-2026, with shareholders demonstrating strong support for the company's strategic initiatives. The e-voting process, which ran from 27th March 2026 to 25th April 2026, resulted in the approval of all three proposed resolutions with requisite majority support under Regulation 44 of SEBI (LODR) Regulations 2015.

Postal Ballot Results Overview

The company sought shareholder approval through remote e-voting on three critical resolutions. Mr. Dharmendra Bhaliya, Practising Company Secretary (C.P. No. 26448), served as the appointed Scrutinizer for the process conducted by MUFG Intime India Private Limited.

Resolution-wise Voting Results

Resolution 1: Healthcare Expansion Funding

The special resolution for interim utilisation of funds towards healthcare expansion received unanimous support from shareholders.

Resolution 2: Financial Statements Revision

The resolution for voluntary revision of financial statements and board's report under Section 131 of Companies Act 2013 received strong support, with minimal opposition.

Resolution 3: Secretarial Auditor Appointment

The ordinary resolution to appoint Mr. Dharmendra Bhaliya as Secretarial Auditor for FY 2025-26 was approved with strong majority support.

Shareholder Participation Analysis

The postal ballot witnessed significant participation across different shareholder categories. The company's total shareholding of 78,843,250 shares saw 56,846,254 votes being cast, representing 72.1003% participation in the e-voting process.

Regulatory Compliance and Process

The postal ballot process was conducted in strict adherence to regulatory requirements. The company published the postal ballot notice dated 19-03-2026 and ensured compliance with SEBI (LODR) Regulations 2015. The cut-off date for determining eligible shareholders was set as 20th March 2026, and the voting period extended for 30 days as mandated by regulations. The scrutinizer's report confirmed that all procedural requirements were met, including proper notification to stock exchanges BSE Limited and National Stock Exchange of India Limited.

Gujarat Kidney and Super Speciality Limited has paid regulatory fines totaling Rs 20,000 to both major Indian stock exchanges for non-compliance with SEBI listing regulations. The healthcare company confirmed the payment in a regulatory filing dated April 20, 2026, addressing violations related to board meeting intimation requirements.

Regulatory Penalties and Payment Status

Both BSE Limited and National Stock Exchange of India Limited had imposed identical fines of Rs 10,000 each on the company for regulatory non-compliance. The penalties were initially communicated on April 15, 2026, through official email notifications from both exchanges. The company has now confirmed payment of these fines on April 16, 2026, through NEFT transfer to both exchanges.

Nature of Violation

The fines were imposed for the company's failure to furnish prior intimation about board of directors meetings as mandated under Regulation 29(2)/29(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation requires listed companies to provide advance notice to stock exchanges before conducting board meetings. The company acknowledged the delay in complying with these disclosure requirements.

Impact Assessment

Gujarat Kidney and Super Speciality Limited's management has assessed the impact of these penalties on business operations. The company confirmed that the levy of fines does not affect its financial, operational, or other activities.

Regulatory Compliance Framework

The disclosure was made pursuant to Regulation 30 of SEBI Listing Regulations, 2015, which requires companies to inform exchanges about material events and regulatory actions. The company provided detailed information about the violations, penalties, and payment status in Annexure-A format as prescribed by SEBI circulars. The regulatory filing was digitally signed by Managing Director Pragnesh Bharpoda (DIN: 01033141) and submitted to both exchanges' listing departments.